Boehringer Ingelheim

This study tests a once-weekly injection called survodutide in 1590 adults with NASH/MASH cirrhosis. Participants receive either the drug or a placebo for up to 4.5 years, along with diet and exercise advice. The goal is to see if survodutide reduces serious liver events like liv…

This study tests the long-term safety and effectiveness of the drug nerandomilast in people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). Participants must have completed a prior nerandomilast study. Everyone receives the drug for up to 22 mont…

This study is testing whether two different versions of the drug survodutide are equally effective in the body. It involves 80 healthy overweight or obese adults who will receive both formulations in a crossover design. The goal is to see if the new formulation matches the origin…

This study tests a weekly injection called survodutide in 1800 adults with MASH (a fatty liver disease) and moderate to advanced liver scarring. Participants are randomly assigned to receive the drug or a placebo for up to 7 years. The goal is to see if survodutide can reverse li…

This study tests a drug called nerandomilast in 400 adults with lung scarring caused by autoimmune rheumatic diseases like rheumatoid arthritis or scleroderma. Participants take the drug or a placebo twice daily for at least 26 weeks while continuing their usual medications. The …

This study tests if spesolimab can close painful skin ulcers in people with pyoderma gangrenosum, a rare condition. About 90 adults with at least one ulcer will receive either spesolimab or a placebo, plus steroids, for up to 1.5 years. The goal is to see if the drug leads to com…

This study tests an oral medicine called BI 1815368 for people with diabetic macular edema, a condition that causes vision loss. About 300 adults will take either the drug or a placebo tablet twice daily for 11 months. Researchers will check if the treatment improves vision by me…

This study tests a new targeted drug called zongertinib, which blocks the HER2 protein that fuels cancer growth, in combination with standard chemotherapy (with or without the immunotherapy pembrolizumab). It is for people with advanced or metastatic non-squamous non-small cell l…

This Phase 3 study tests whether adding vicadrostat to the standard drug empagliflozin helps adults with chronic heart failure and a weak heart pump. About 4200 participants will take either the combo or a placebo plus empagliflozin daily for up to 3.5 years. Researchers will tra…

This study tests an experimental oral drug called BI 3000202 in 405 adults with moderate to severe systemic lupus erythematosus (SLE). Participants are randomly assigned to one of four doses of BI 3000202 or a placebo, taken daily for a year alongside their usual lupus treatments…

This study tests a new drug, BI 3820768, in adults with advanced germ cell, endometrial, or ovarian cancers that have not responded to prior treatments. The drug aims to help the immune system fight cancer. Researchers will give increasing doses to find a safe and tolerable dose,…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This study tests a new drug called BI 3032950 in 80 adults with moderate to severe ulcerative colitis who haven't improved on other treatments. In the first part, the drug is given by IV every 4 weeks for 12 weeks. Those who respond then receive injections under the skin every 4 …

This study tests an experimental drug called zongertinib, which blocks HER2—a protein that fuels cancer growth. It is for adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and no longer responds to standard treatments. Participants receive zongertin…

This early-stage study tests a new medicine, BI 765049, in adults with advanced colorectal, stomach, or pancreatic cancer that cannot be removed by surgery or has spread. The main goal is to find the highest safe dose and the best way to give the drug. BI 765049 is designed to he…

This study tests whether adding vicadrostat to the standard medicine empagliflozin helps people with heart failure who have a preserved ejection fraction (heart pumps normally but is stiff). About 6000 adults with symptoms will take either vicadrostat plus empagliflozin or a plac…

This early-phase study tests a new experimental drug (BI 3819026) alone and with another drug (ezabenlimab) in adults with advanced solid cancers that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. About 60 particip…

This study tests a new medicine called BI 3802876 in 29 adults with compensated cirrhosis caused by MASH, a type of fatty liver disease. Participants receive either the drug or a placebo as an infusion, and researchers monitor safety and how the body processes the drug over about…

This study tests an experimental tablet, BI 764198, in adults and some teens with four types of kidney disease that cause protein in the urine. Participants take the drug or a placebo daily for 20 weeks while continuing their usual care. The main goal is to see if the drug lowers…

This early-stage study tests a new drug called BI 3810944 in adults with advanced solid tumors or melanoma who have run out of treatment options. The main goals are to find safe doses and see if the drug can shrink tumors. Participants receive the drug every three weeks, with mor…

This study tests an oral medication called BI 764198 for people with a kidney condition called focal segmental glomerulosclerosis (FSGS). About 286 adults and teens will take either the study drug or a placebo daily for up to 2 years, while continuing their usual FSGS treatments.…

This study tests whether adding the experimental drug vicadrostat to the standard medicine empagliflozin can lower the risk of heart problems in adults with type 2 diabetes, high blood pressure, and existing heart disease. About 11,800 participants will take either the combinatio…

This study tests a daily tablet called BI 1291583 to see if it can reduce the number of lung flare-ups (exacerbations) in people with bronchiectasis. About 1,755 adults and teens aged 12 and older who produce sputum and have had prior flare-ups will take either the study drug or …

This study tests whether the clot-busting drug tenecteplase can help people recover from a stroke when given more than 4.5 hours after symptoms began or waking up with stroke. About 1,325 adults with brain tissue still salvageable will be randomly assigned to receive tenecteplase…

This study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…

This early-phase study tests obrixtamig, a drug that helps the immune system attack cancer cells, in adults with advanced small cell lung cancer or other neuroendocrine cancers that have a specific marker called DLL3. Participants receive the drug weekly or every three weeks for …

This study tests an experimental drug called BI 764532 (obrixtamig) in adults with advanced small cell lung cancer or other neuroendocrine cancers that have stopped responding to treatment. The drug is designed to help the immune system attack cancer cells. The main goals are to …

This study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find a safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then …

This study tests a new medicine called BI 765423 in adults aged 40 and older with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and makes breathing hard. About 71 participants will receive either the study drug or a placebo (a dummy treatment) as an inf…

This study tests a new medicine called BI 3812465 for people with diabetic macular edema, a condition that causes swelling in the center of the eye and can lead to vision loss. The trial has two parts: first, a small group gets low to high doses to check safety, then a larger gro…

This study tests whether adding the experimental drug BI 690517 to the existing medicine empagliflozin can slow kidney disease and prevent heart problems in adults with chronic kidney disease. About 11,000 participants will take either BI 690517 or a placebo, plus empagliflozin, …

This study tests whether a daily pill called zongertinib can help prevent lung cancer from coming back in people with early-stage (Stage II-IIIB) non-small cell lung cancer that has a specific HER2 mutation. All participants have had surgery to remove their tumor and standard che…

This study tests whether empagliflozin, a medicine already used for diabetes, can help children aged 2 to 17 with chronic kidney disease. About 120 kids will take either the drug or a placebo for 6 months, then everyone gets the drug for a year. Researchers will check kidney func…

This study tests a medicine called nerandomilast in people aged 40+ who have a family member with pulmonary fibrosis and early lung changes on scans. The goal is to see if the drug can slow or prevent worsening of lung damage. Participants take a tablet twice a day for about 2-3 …

This early-stage study tests whether a new medicine called BI 3031185 is safe and well-tolerated in adults with borderline personality disorder (BPD) or attention-deficit/hyperactivity disorder (ADHD). About 96 participants will receive either the drug or a placebo in a crossover…

This early-stage trial is testing a new drug called BI 3814916 in 136 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure drug levels in the blood. Thi…

This study looks at how interstitial lung disease (ILD) affects people with rheumatic diseases like rheumatoid arthritis and lupus in Mexico. Researchers will track 312 patients over time to see how the lung disease progresses and what factors might make it worse. The goal is to …

This early-stage study is recruiting 44 adults aged 18 to 80, including both healthy people and those with liver problems. All participants will take a single tablet of the drug BI 3000202. Researchers will measure how the drug moves through the body and check for side effects ov…

This study looks at how a single dose of the experimental drug BI 1291583 behaves in the blood of people with and without liver problems. The drug is being developed for bronchiectasis, a chronic lung disease. About 32 adults aged 18–80 will take part, divided into groups based o…

This study uses a special PET scan to see how the experimental drug BI 764532 travels through the body and reaches tumors. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers who have run out of standard treatment options. The main goal is to mea…

This study tests whether a single dose of vicadrostat affects the heart's electrical activity in 45 healthy adults aged 18 to 50. Participants receive vicadrostat, placebo, or moxifloxacin in random order, and heart rhythms are monitored for 24 hours. The goal is purely safety-re…

This early-stage study tests a new drug called BI 3821001 in healthy men aged 18 to 55. The main goal is to check if the drug is safe and how the body processes it. Participants receive a single dose and are monitored for side effects. No direct health benefit is expected, but th…

This early-stage study is testing a new drug called BI 3031185 in 100 healthy adults to see if it is safe and how the body handles it. Participants will take multiple doses of the drug or a placebo. The goal is to gather safety information, not to treat any disease.

This early-stage trial is testing a new drug called BI 3804379 in healthy adults to see if it is safe and how the body processes it. About 106 healthy men and women aged 18 to 65 will receive either the drug or a placebo as a shot under the skin. The study focuses on side effects…

This study looks at how pirfenidone changes the amount of a new medicine (BI 1015550) in the blood of adults with idiopathic pulmonary fibrosis (IPF). Twenty participants aged 40 and older will take both drugs over about a month. Researchers will measure blood levels to understan…

This early-stage study looks at how the experimental drug BI 456906 attaches to receptors in the liver and pancreas that control appetite and weight. About 30 adults with obesity will receive either BI 456906 or the approved weight-loss drug semaglutide for 17 weeks. Researchers …

This early-stage trial is testing a new drug called BI 3776528 in healthy men aged 18 to 50. The main goal is to see if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo. This study does not aim to treat any disease.